SUMMARY Platelet survival and splenic sequestration patterns were studied in 32 patients with thrombocytopenia using donor platelets labelled with chromium-5 1. A shorter mean platelet lifespan was observed in immune thrombocytopenia (ITP) (mean 12 hours) than in hypersplenism (mean 56 hours) or marrow hypoplasia (mean 102 hours). There was no such correlation between diagnosis and splenic sequestration. A biphasic survival curve was seen in nine of 22 patients with ITP. Thirteen patients underwent splenectomy with complete (9) or partial (4) response, but no consistent pattern of results was manifest. It is concluded that in vivo isotope studies are of little value in predicting the benefit of splenectomy in thrombocytopenic patients, although they may demonstrate the mechanism of the thrombocytopenia, in particular the biphasic survival curve revealing separate 'immune' and 'hypersplenic' components of platelet destruction in ITP.
Thrombocytopenia may be due to decreased platelet production or to an increased rate of destruction. Increased destruction may be due to hypersplenism, immunological mechanisms, or a combination of both. Determination of the pattern of platelet survival and of the degree of splenic platelet sequestration may help to elucidate the underlying mechanism of destruction and have been proposed as useful investigations for the prediction of the outcome of splenectomy in thrombocytopenic patients.
Review of the literature
The earliest determinations of platelet lifespan were carried out by transfusion of platelet-rich whole blood into thrombocytopenic recipients (Hirsch and Gardner, 1952) . Schwartz (1974) measured the recovery of platelet aggregation after the ingestion of acetylsalicylic acid, normal aggregation being restored in two or three days in patients with immune thrombocytopenic purpura vITP), other autoimmune diseases, and splenomegaly due to thalassaemia or sickle trait, whereas in control subjects the time was four to seven days. The majority of subsequent techniques have involved the use of radioactive labels, including 32P-di-isopropyl phosphate (Adelson et al., 1957; Leeksma and Cohen, 1956 ), 14C-serotonin (Heyssel, 1961) , 75Se-selenomethionine Received for publication 9 May 1979 (Cohen et al., 1965) , and 51Cr-sodium chromate (Aas and Gardner, 1958) . Murphy and Gardner (1971) demonstrated that the results of platelet lifespan measurements are dependent on several procedural factors other than the technique used for labelling, namely, the type of anticoagulant, the nature of the wettable surface of the containers, and the immunological compatibility of the platelets.
Labelling with 51Cr has teen found to be a satisfactory method for the following reasons: the isotope becomes firmly bound to the platelets within 20 minutes; the slow rate of isotope elution allows this factor to be disregarded in calculations; the energy spectrum of the gamma emissions is suitable for in vivo as well as in vitro counting within an acceptable dose to the patient (less than 50 .t Ci). The platelet lifespan in normal subjects has been estimated to be nine to 11 days (216-264 hours) (Harker and Finch, 1969) . The value of isotope studies in thrombocytopenia has been controversial. A close correlation between splenic sequestration and the benefit of splenectomy was demonstrated by Najean et al. (1967) . The site of sequestration in ITP was further studied by these workers (Najean and Ardaillou, 1971) , who concluded that where splenic sequestration can be clearly demonstrated, splenectomy gives both short-and long-term remission. They also suggested that the site of sequestration was not related to either the severity or the duration of the disease. However, these findings were in contradiction to those of Aster and Keene (1969) , who sug-gested that sequestration could be related to the severity of the disease at the time of study and was of no value in deciding the benefit of splenectomy. Barkhan (1974) stated that, in chronic ITP, 'spleen scanning after infusing 51Cr-labelled platelets is not useful for selecting patients for splenectomy'. The exchangeable splenic pool of platelets has been studied in healthy subjects and in patients with splenomegaly of varying aetiology by Branehog et al. (1973) . It was larger in patients with splenomegaly than in controls or patients suffering from ITP. However, the recovery of labelled platelets in these patients with ITP was less than in normal subjects, and therefore the exchangeable splenic platelet pool in ITP could not be determined by this method.
Patients and methods
Platelet survival studies were carried out on 32 patients with marked thombocytopenia (platelet counts 10-50 x 109/l). Seventeen were male, 15 female, and their ages ranged from 5 to 70 years. Of these, 22 were diagnosed as suffering from ITP, 16 of acute onset one week to six months before the date of investigation, and six with a chronic history extending from 18 months to five years before investigation. Nine of the acute and three of the chronic cases had been treated with prednisone before investigation without significant improvement of the platelet count. Five patients had splenomegaly secondary to other diseases (Gaucher's disease, myelofibrosis, and portal hypertension) with documented thrombocytopenia for two months to nine years, and five had impaired platelet production with thrombocytopenia for one month to 13 years before investigation. All patients in these two groups were untreated at the time of investigation except one with phenylbutazone-induced marrow hypoplasia, who had received prednisone, oxymetholone, and platelet transfusions and is discussed further below.
Heterologous pooled platelet concentrates from five normal ABO portional to whole blood platelet activity in the original specimen, provided the preparation of the PRP is carefully standardised, and represents the proportion of the original injected dose still circulating. Good agreement was found between duplicates, and this method was preferred to the more usual expression of activity as a function of the platelet count in the PRP. The latter represents the proportion of circulating platelets still carrying the label, and calculation of survival on this basis will be subject to errors due to independent variation in numbers of unlabelled platelets during the time of the study. Total counts recorded were in the range 5000-20 000 but occasionally fell to 1-2000 in late specimens (variance 5-10%).
Results were expressed as a percentage of the peak post-injection activity and plotted against time on semilogarithmic paper. Mean platelet lifespan (MPL) was derived from the graph according to the formula: MPL= TJ51Cr TJ 51Cr loge 2 0-69 assuming an exponential loss of platelets from the circulation (Ries and Price, 1974) . In those with biphasic curves, the initial slope was extrapolated where necessary to obtain the TJ of the short-lived population. Tables 1 and 2 . There was no correlation between the length of history of the ITP patients, or previous treatment, and any of the parameters measured or the need for subsequent splenectomy or its outcome.
Results

Details of patients and individual results are given in
Two patterns of platelet survival were identified: a single exponential curve (Fig. 1) was seen in patients with reduced production and those with secondary hypersplenism and in eight of 22 patients with ITP. On the other hand, nine of the latter group showed evidence of a double population with a biphasic survival curve (Fig. 2) . In five patients with ITP the curves obtained did not fall clearly into either pattern. Splenic sequestration, as assessed by the spleen/heart ratio, varied widely and showed no significant correlation with diagnosis ( Fig. 3) , mean platelet lifespan, or shape of survival curve.
Mean platelet lifespan was 20 minutes to 75 hours (mean 12 hours) in ITP, and 30-87 hours (mean 56 hours) in secondary hypersplenism, compared with 77-129 hours (mean 102 hours) in marrow hypoplasia (Fig. 3) . The mean lifespan tended to be shorter in those with biphasic curves although there was no correlation with the severity of the thrombocytopenia or with the degree of splenic sequestration. Of those with ITP, 13 After the injection of labelled heterologous. platelets, two factors influence splenic sequestration: (i) the degree of hypersplenism, dependent upon the splenic circulation through the pulp cords (as. opposed to the normal sinusoidal pathway), and! endothelial adhesiveness of the sinus walls and pulp cord spaces; and (ii) the changes of the platelet surface due to antibody coating.
The first factor alone results in a single exponential platelet disappearance curve, whereas the effects of both together produce the biphasic curve found in some patients with immune thrombocytopenia. This type of curve has not been seen in patients with othertypes of thrombocytopenia, except in one with hypoplastic anaemia who had received many platelet transfusions. The presence of both components will be apparent only if their time courses are substantially different; otherwise a single exponential or in--determinate curve will be seen. This depends on the relative importance of the hypersplenic and immune FFemale 35yr components, and it is not possible to decide in an individual patient which is producing the fast and which the slow phase of the survival curve. It would be of considerable interest to repeat the investigation after splenectomy in cases where the presplenectomy survival curve was biphasic but was not thought to be ethically justifiable. The immune component is the major factor in the failure of splenectomy due to increased destruction in the liver, and this is dependent on the amount of antibody activity carried by the platelets, that is, the product of antibody protein quantity and antibody avidity. Although measurement of the former is now an established technique (Dixon et al., 1975) , the latter is not, and without it one cannot expect a close correlation between other investigations and the clinical outcome.
